Vir(VIR) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results – ECLIPSE registrational program in chronic hepatitis delta fully underway – First patient dosed in Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager; advancing oncology clinical pipeline with three ongoing Phase 1 studies – Strong financial position and runway into mid-2027 with approximately $892.1 million in cash and investments as of June 30, 2025 – Conference call s ...